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A B S T R A C T
The aggregation of ﬁbrils of hyperphosphorylated and C-terminally truncated microtubule-associated tau protein characterizes 80% of all dementia disorders, the
most common neurodegenerative disorders. These so-called tauopathies are hitherto not curable and their diagnosis, especially at early disease stages, has tradi-
tionally proven diﬃcult. A keystone in the diagnosis of tauopathies was the development of methods to assess levels of tau protein in vivo in cerebrospinal ﬂuid,
which has signiﬁcantly improved our knowledge about these conditions. Tau proteins have also been measured in blood, but the importance of tau-related changes in
blood is still unclear. The recent addition of positron emission tomography ligands to visualize, map and quantify tau pathology has further contributed with
information about the temporal and spatial characteristics of tau accumulation in the living brain. Together, the measurement of tau with ﬂuid biomarkers and
positron emission tomography constitutes the basis for a highly active ﬁeld of research.
This review describes the current state of biomarkers for tau biomarkers derived from neuroimaging and from the analysis of bodily ﬂuids and their roles in the
detection, diagnosis and prognosis of tau-associated neurodegenerative disorders, as well as their associations with neuropathological ﬁndings, and aims to provide a
perspective on how these biomarkers might be employed prospectively in research and clinical settings.
1. Introduction
Proteinopathies are diseases where pathogenic post-translational
modiﬁcations (PTMs), such as excess phosphorylation, misfolding, and
aggregation of proteins are unregulated and misfolded proteins accu-
mulate, harming cells and their environment (Fontaine et al., 2015; Ren
et al., 2014; Walker and LeVine 3rd, 2012). Disorders associated with
the accumulation of the microtubule-associated protein tau are thus
termed tauopathies. Tau, among other physiological roles, stabilizes
microtubules and maintains synaptic integrity and function. Under
pathological conditions, however, its amyloidic (“starch-like”) nature
(Sipe et al., 2016) results in self-aggregation into aberrant ﬁbrillar β-
sheet structures, which accumulate intracellularly and cause synaptic
dysfunction and degeneration (Iqbal et al., 2016). Six isoforms of tau
are expressed in the human brain, resulting from alternate splicing of
the MAPT gene on chromosome 17 and diﬀering in the number of
amino terminal inserts (0/1/2N) and the number of microtubule-
binding domain repeats, either three (3R) or four (4R) (Goedert et al.,
1989). The neuropathology of diﬀerent tauopathies exhibits varying
isoform composition of the diﬀerent intracellular tau inclusions as well
as distinct neuroanatomical distribution and relative amounts of tau
inclusions. Common tauopathies include certain variants of fronto-
temporal lobe dementia (FTD) - frontotemporal lobar degeneration-tau
(FTLD-tau) (Mackenzie and Neumann, 2016) - such as autosomal-
dominant FTLD-17, where mutations in MAPT cause mixed 3R/4R tau
inclusions whose grey and white matter distribution can overlap with
sporadic tauopathies; Pick's disease (PiD), characterized by so-called
Pick bodies, round inclusions formed almost exclusively by 3R tau ag-
gregating along spatial phases in neocortical layers II-IV and certain cell
populations of the hippocampus (Irwin et al., 2016); progressive
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nuclear palsy (PSP), characterized by predominant 4R tau inclusions
mainly in speciﬁc nuclei of the basal ganglia, diencephalon, brainstem
and cerebellum, with limited involvement of the neocortex (Dickson
et al., 2010); corticobasal degeneration (CBD) with 4R-dominant tau
pathology grossly overlapping with PSP with a tendency to greater
involvement of the cerebral cortex and especially white matter (Dickson
et al., 2011; Ouchi et al., 2014); and Alzheimer's disease (AD), which
accounts for the vast majority of tauopathy cases and is characterized
by mixed 3R/4R mixed tau pathology accumulating in distinct spatial
and temporal stages (Braak stages, see below) (Braak and Braak, 1991;
Braak et al., 2011).
In 1906, Alois Alzheimer presented what he had found in the brain
of the alleged ﬁrst patient to be diagnosed with AD. What he described
as “Eigentümliche Veränderungen der Hirnrinde” (“Peculiar changes of
the brain's cortex”) at a conference in Tübingen, Germany, was likely
the ﬁrst description of AD-typical neuroﬁbrillary tangle pathology,
which together with plaques, composed of ﬁbrillar β-amyloid (Aβ)
protein, constitute the macropathological hallmarks of AD. It would
take another 80 years until hyperphosphorylated tau was identiﬁed as a
core component of AD-related paired helical ﬁlaments (PHF), the main
components of neuroﬁbrillary tangles (NFT) (Grundke-Iqbal et al.,
1986a; Grundke-Iqbal et al., 1986b; Ihara et al., 1986; Kosik et al.,
1986; Wood et al., 1986). Another decade later, in vivo assessment of
tau became possible through the development of assays for the detec-
tion of total (T-tau) and phosphorylated tau (P-tau) in cerebrospinal
ﬂuid (CSF) (Blennow et al., 1995). Five years ago, positron emission
tomography (PET) ligands binding to tau with high aﬃnity were in-
troduced, enabling the visualization, mapping, and quantiﬁcation of tau
in the living brain (Chien et al., 2013).
Ongoing treatment trials targeting tau pathology now call for reli-
able and quantiﬁable tau biomarkers for the early identiﬁcation of
eligible study participants and the in vivo quantiﬁcation of potential
treatment eﬀects (Cummings et al., 2018; Khanna et al., 2016). Fur-
thermore, the National Institute on Aging and Alzheimer Association
(NIA-AA) research criteria in the diagnosis of AD (Jack Jr. et al., 2018a)
have implemented the use of tau biomarkers derived from PET and CSF,
however, it remains unclear how the diﬀerent biomarkers may be op-
timally operationalized.
Here, we summarize the current state of ﬂuid- and imaging-derived
markers for tau pathology.
2. Fluid biomarkers of tau
2.1. Tau in CSF
Over three decades ago, the ﬁnding that P-tau was the major com-
ponent of tangles (Grundke-Iqbal et al., 1986b) made tau proteins in
CSF prime candidates for quantitative immunoassays. Today, both CSF
T-tau and P-tau assays (along with low Aβ42) are central to the Internal
Working Group (IWG) (Dubois et al., 2014) and the NIA-AA (Jack Jr.
et al., 2018a) research criteria in the diagnosis of AD. In AD, neurons
release more tau proteins to the extracellular space, which is reﬂected
in CSF from patients as increased concentrations of both T-tau, mea-
sured using antibodies against mid-domain tau epitopes that are not
phosphorylated, and P-tau that is measured using antibody combina-
tions that speciﬁcally recognize mid-domain P-tau epitopes (Olsson
et al., 2016). These biomarker changes correlate with each other,
however, this association is most pronounced in AD and less pro-
nounced for isolated increases in T-tau (Skillback et al., 2015). CSF T-
tau and P-tau correlate with AD-type neurodegeneration and tangle
pathology in autopsy and biopsy studies (Buerger et al., 2006; Seppala
et al., 2012; Tapiola et al., 2009), but the correlations are modest, and
not reported in all studies (Engelborghs et al., 2007). This appears to be
diﬀerent from correlation studies between tau PET imaging and CSF tau
biomarkers (see below), and immediately suggest diﬀerences in how
these diﬀerent biomarker modalities reﬂect the underlying processes in
AD.
CSF T-tau has been postulated to reﬂect the severity of acute injury
and/or on-going neurodegeneration (Blennow and Hampel, 2003). CSF
T-tau is likely increased very early in the disease process since increased
levels can be seen already in Aβ-positive cognitively unimpaired in-
dividuals (CU) (while other markers of injury, including neurogranin
and neuroﬁlament light protein were not increased until the prodromal
stage in the same cohort (Mattsson et al., 2016a)). However, the in-
crease in CSF T-tau is not speciﬁc to AD, since CSF T-tau levels are the
highest in conditions with the most severe neurodegeneration, in-
cluding Creutzfeldt-Jakob disease, which has been shown to be>10-
times higher in T-tau concentrations than dementia (Skillback et al.,
2014). Following acute brain injury, a rapid spike in CSF T-tau is ob-
served and maintained for a number of weeks before slowly declining to
normal levels (Hesse et al., 2001; Zetterberg et al., 2006). In AD, higher
T-tau values predict a more rapid cognitive decline (Buchhave et al.,
2012; Wallin et al., 2010), and relate to more rapid hippocampal
atrophy and reductions in FDG-PET binding (Mattsson et al., 2016a;
Chiaravalloti et al., 2018), which supports the idea that T-tau levels are
related to the intensity of neurodegeneration.
Several validated commercially available immunoassays targeting
threonine 181 (P-tau181) consistently demonstrate an increase in AD.
However, other mid-domain P-tau residues (threonine 231, serine 199
and 231) and C-terminal residues (Serine 396 and 404) are also in-
creased in AD (Hu et al., 2002; Ishiguro et al., 1999; Kohnken et al.,
2000). A limited number of studies seem to demonstrate co-linearity
but speciﬁcity in P-tau181, 199 and 231 to distinguishing AD from
other neurodegenerative disorder and aged healthy controls (Hampel
et al., 2004).
A major outstanding research question is why other tauopathies,
including some forms of FTD and associated disorders like PSP, do not
show increased P-tau concentration in the CSF, at least not as robustly
as in AD (Zetterberg, 2017). It is possible that disease-speciﬁc phos-
phorylation of tau occurs in these disorders, or that tau is processed or
truncated in a way that is not recognized by the available assays. An-
other potential explanation for why increased CSF T-tau and P-tau are
speciﬁc to AD is that this particular pathological change is simply more
extensive and severe in AD than in other tauopathies. However, this
seems contradicted by the fact that some non-AD tauopathy patients,
most notably PSP patients, even have decreased CSF P-tau levels com-
pared to control populations (Hall et al., 2012; Meeter et al., 2018;
Wagshal et al., 2015).
Yet another possibility is that CSF T-tau and P-tau increase reﬂects a
neuronal response to Aβ pathology, which precedes neurodegeneration
and tangle pathology, as suggested by mouse model studies (Maia et al.,
2013) and tau kinetics studies in humans (Sato et al., 2018). This is in
agreement with the poor correlation between CSF T-tau and P-tau with
[18F]Flortaucipir (FTP) imaging in early stages of AD, as discussed
further below.
It is known that the major proportion of tau is cleaved to N-term-
inally truncated or N-terminal to mid domain fragments before being
secreted to the CSF, while C-terminal fragments are much less abundant
(Barthelemy et al., 2016; Meredith Jr. et al., 2013). Recent studies have
identiﬁed tau species cleaved by asparagine endopeptidase (AEP), that
generate tau fragments ending at amino acid 368 (based on tau 2 N/4R
tau numbering), which are up-regulated in aging and AD, and which
have an increased tendency for aggregation into tangles (Zhang et al.,
2014). Future research to evaluate if tau368 or other C-terminally ex-
tended tau fragments measured in CSF may serve as biomarkers for tau
pathology is warranted.
2.2. Tau in plasma
Both imaging (see below) and CSF biomarkers work well to identify
AD pathophysiology. Nonetheless, PET imaging is costly and access is
restricted to specialized centers. Gradually, CSF sampling for analysis of
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AD biomarkers is becoming increasingly used in clinical practice for
management of neurodegenerative diseases, yet there remains a level of
perceived invasiveness or complexity attached to a lumbar puncture in
many countries. The accessibility and ease of blood sampling provides
signiﬁcant practical advantages for measuring AD biomarkers, for both
clinical assessment or screening and repeated sampling in therapeutic
trials.
Blood communicates with the brain across the blood-brain barrier,
via lymph vessels and through the glymphatic system (Plog and
Nedergaard, 2018; Zetterberg and Blennow, 2018). Despite this, it has
proven diﬃcult to establish the core CSF biomarkers for AD pathology
in blood. Firstly, due to its continuous and uninhibited exchange with
the brain, biomarkers in CSF will be considerably higher in con-
centration than biomarkers in blood. Furthermore, once entering the
bloodstream, brain-derived proteins will compete in a complex matrix
of highly abundant plasma proteins (e.g. albumin, IgG, transferrin,
haptoglobin, and ﬁbrinogen) that span> 10 orders of magnitude.
Secondly, a brain-derived biomarker may undergo protease degrada-
tion, metabolized by the liver and cleared by the kidneys or simply have
substantial expression by peripheral tissues. Lastly, analytical factors
such as interference from heterophilic antibodies or variations in blood
collection, processing and storage can have a major inﬂuence on an
individual result. All these factors will introduce a high degree of
variability that is unrelated to the disease pathogenesis and will be
diﬃcult to normalize.
In the advent of emerging ultrasensitive techniques that resolve
confounding matrix eﬀects, the femtomolar detection of proteins in
blood has been demonstrated (Rissin et al., 2010). Indeed, increased
plasma levels of T-tau in AD compared to CU and/or MCI (mild cog-
nitive impairment) have been exhibited by immunomagnetic reduction
(IMR) (Tzen et al., 2014) and Single molecule array (Simoa) (Zetterberg
et al., 2013). More recently, in the ADNI and BioFINDER cohorts, this
ﬁnding was conﬁrmed but with large overlaps between the clinical
groups, which almost certainly concludes that plasma T-tau is not di-
agnostically useful in a cross-sectional manner (Mattsson et al., 2016b).
Conversely, baseline plasma T-tau might be useful in predicting future
cognitive decline (Mattsson et al., 2016b; Mielke et al., 2017), atrophy
and hypermetabolism (Mattsson et al., 2016b). Likewise, in cardiac
arrest, with much greater acute neuronal injury than AD, baseline
plasma T-tau may be used for prognosis of patients with poor
neurological outcome (Mattsson et al., 2017c). Plasma T-tau, however,
correlates poorly with CSF T-tau (Mattsson et al., 2016b; Zetterberg
et al., 2013), which might have several explanations, e.g. rapid per-
ipheral degradation of tau or that blood tau levels are confounded by
expression of tau in peripheral tissues. As with CSF, assays directed
towards truncated fragments of tau in plasma may yield greater disease
speciﬁcity.
At this time there is no validated assay for P-tau in blood.
Nonetheless, recent pilot data have reported encouraging ﬁndings. The
Simoa and Meso Scale Discovery (MSD) platforms have both been uti-
lized to demonstrate an increase of P-tau181 concentration in AD pa-
tients compared to healthy controls (Mielke et al., 2018; Tatebe et al.,
2017). Importantly, however, both these studies reported weak but
signiﬁcant correlations with either CSF P-tau181 (Tatebe et al., 2017)
or FTP (Mielke et al., 2018). Intriguingly, the stated concentrations of
P-tau181 between the two methods diﬀer substantially (Simoa assay
reported a mean concentration of 0.171 pg/mL in AD patients versus
12 pg/mL on the MSD platform). In another recent paper, plasma P-
tau231 was measured using a ﬁber optics technique in which antibody-
based detection was combined with rolling circle ampliﬁcation
(Rubenstein et al., 2017). Increased concentrations of plasma P-tau231
in patients with traumatic brain injury (TBI) were observed but as of yet
no data has been reported in AD. This promising data, albeit pre-
liminary, on P-tau makes it one of the most anticipated areas of AD
biomarker research alongside plasma Aβ42/Aβ40 (Ashton et al., 2018a,
2018b) and neuroﬁlament light chain (Mattsson et al., 2017a).
Other areas of ongoing investigation for peripheral tau include, but
are not limited to, exosomes and saliva. Increases in T-tau and P-tau
within neuronal-derived exosomes in plasma have been a developing
area of research (Fiandaca et al., 2015; Winston et al., 2016). As it
stands, further validation of these results and methodologies are
needed. It has previously been shown that T-tau is readily measurable
in saliva (Ashton et al., 2018a). While concentrations are noticeably
higher than plasma, no statistically signiﬁcant diﬀerence across diag-
nostic groups was observed. Preliminary proteomic data suggests that
certain P-tau fragments derived in saliva may be of importance in
clinical AD, however this is yet to be determined using a robust plat-
form in large sample sizes.
Fig. 1. Chemical structures of current PET ligands binding to PHF tau protein.
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3. Tau positron emission tomography (PET)
Given the molecular diversity of tauopathies, it cannot be assumed
that one PET ligand or even one class of chemically similar PET ligands
will be useful in the research of all disorders. Several companies and
academic groups have developed and are continuously developing li-
gands presumably binding to tau (please refer to Fig. 1 for the chemical
structures of current alleged tau PET ligands). Based on the recently
published cryo-EM structure for the tau ﬁbril (Fitzpatrick et al., 2017),
four binding sites have been suggested for current PET ligands, and
diﬀerent candidates show diﬀerential preference for each of these sites
(Murugan et al., 2018).
3.1. First-generation tau PET ligands
The ﬁrst PET ligand used to visualize the molecular underpinnings
of AD was [18F]FDDNP (Shoghi-Jadid et al., 2002), which binds to both
Aβ ﬁbrils and tau NFT. Due to its relative nonspeciﬁcity for one or the
other it has largely been replaced by tau or Aβ-speciﬁc ligands.
One of the earliest agents developed speciﬁcally for tau imaging was
the carbon-11 labelled PBB3, a pyrinated phenyl- and pyridinyl-buta-
dienyl-benzothiazole with a 50-fold higher aﬃnity to tau over Aβ de-
posits (Maruyama et al., 2013). [11C]PBB3 was initially found to exhibit
aﬃnity to tau in AD, PSP and CBD tissue samples (Ono et al., 2017b),
however its utility was hampered by high white matter uptake, low
target to white matter ratio on autoradiography in AD tissue, its fast
metabolism in vivo (< 8% remaining 3min after injection) (Hashimoto
et al., 2014), photo-isomerization upon exposure to ﬂuorescent light,
and a dominant brain-penetrant metabolite that complicated quantiﬁ-
cation of ligand uptake (Hashimoto et al., 2015). Finally, carbon-11
labelling with its short half-life (~20min) limits potential use of any
PET ligand as compared to ﬂuorine-18 labelling (half-life ~ 110min).
To address these issues, the ﬂuorine-18 analogues AM-PBB3 and PM-
PPB3 were developed (Ono et al., 2017a; Shimada et al., 2017a) but
limited data have been published to date.
A series of compounds have been developed at Tohuku University,
Japan, the most widely used being the arylquinoline derivatives
[18F]THK5117 (Okamura et al., 2013) and [18F]THK5351. Of these
two, [18F]THK5351 demonstrated favorable imaging characteristics,
generally demonstrating higher grey matter and lower white matter
uptake but lower lipophilicity (Betthauser et al., 2017a). The S-en-
antiomer form of [18F]THK5117, [18F]THK5317, has also been assessed
in vivo (Chiotis et al., 2016; Jonasson et al., 2016). However, high oﬀ-
target binding of [18F]THK5351 was observed especially in the tha-
lamus, and blocking studies with the monoamine oxidase B (MAO-B)
inhibitor selegiline showed dramatic reduction in thalamic
[18F]THK5351 uptake (Ng et al., 2017a). Cortical uptake was also re-
duced signiﬁcantly, indicating that this oﬀ-target binding also aﬀected
what had been previously assumed to be tau speciﬁc uptake in in vivo
studies (see also below).
The radioligand [18F]Flortaucipir (FTP, previously AV1451 or
T807), a benzimidazole pyrimidine derivative, is the by far most widely
studied tau PET tracer to date. It has been shown to bind with high
aﬃnity (25–27 fold larger than to Aβ) to 3R and 4R tau isoforms in PHF
of AD patients (Chien et al., 2013; Lowe et al., 2016; Marquie et al.,
2015). Smith and colleagues furthermore showed that in vivo FTP-
binding and post-mortem PHF load were highly correlated in one subject
with a MAPT R406W mutation causing AD-like tau pathology (Smith
et al., 2016). However, large inter- and intraindividual diﬀerences were
observed in a recent study in post mortem tissue from several neuro-
degenerative disorders (Wren et al., 2018), calling for further in-
vestigation of the binding characteristics. Nonetheless, on a group level,
FTP demonstrated clinical usefulness when its discriminative accuracy
between AD dementia and non-AD neurodegenerative disorders was
examined in a large multisite study, yielding 89.9% (95% CI,
84.6%–93.9%) sensitivity and 90.6% (95% CI, 86.3%–93.9%)
speciﬁcity or 96.8% (95% CI, 92.0%–99.1%) sensitivity and 87.9%
(95% CI, 81.9%–92.4%) speciﬁcity based on diﬀerent thresholds ap-
plied to medial-basal and lateral temporal cortex ligand uptake
(Ossenkoppele et al., 2018).
The in vivo kinetics of [18F]FTP have been investigated in a number
of studies, aiming at validating semi-quantitative estimates such as the
standardized uptake value ratio (SUVR), which are more appropriate
for clinical research than fully dynamic and quantitative approaches
(Baker et al., 2017a; Barret et al., 2016; Golla et al., 2017; Hahn et al.,
2017; Wooten et al., 2017). In those studies including blood sampling
and metabolite analysis, 20–30% of [18F]FTP was found to remain
60min after injection, with the main metabolites being polar and thus
not entering the brain. Free fraction in plasma was low (0.19%) (Barret
et al., 2016). The diﬀerent studies came to diﬀerent conclusions re-
garding the most appropriate kinetic model to describe ligand uptake.
Whereas the two-tissue compartment model was found to best describe
the data, also in the cerebellar cortex for all subjects including controls
(Barret et al., 2016), others found that in controls the uptake was best
described by the 1-tissue compartment model (Golla et al., 2017), in-
dicating that model preference depended on the underlying volume of
distribution. A third study found that none of the compartment models
adequately described the data (Hahn et al., 2017). Most importantly,
however, all studies found that reference-based quantiﬁcation of dy-
namic data correlated well with arterial blood-based quantiﬁcation
supporting the use of an 80–100 (75–105) min SUVR as an acceptable,
yet not ideal, method for clinical studies (see also (Heurling et al.,
2018) for assessment of how regionally and temporally diﬀerent times
to transient equilibria inﬂuence SUVR reliability). Regional increase of
ligand uptake past 180min in certain high-binding patients might also
inﬂuence semi-quantiﬁcation by SUVR in earlier time frames and needs
to be evaluated further. Finally, analysis of in vivo test-retest reliability
of FTP yielded low variability in SUVR (standard deviation of mean
percent change 1.46–3.27% depending on brain region) (Devous Sr.
et al., 2018).
3.2. Second-generation tau PET ligands
Numerous publications have applied FTP in clinical studies, as de-
scribed in the next section. However, concerns about oﬀ-target binding
issues (see below) have triggered the continuous development of a
second generation of tau PET ligands. As data on most of these novel
compounds have only been published or presented very recently, no
head-to-head comparison has been conducted including any of these.
Fig. 2 therefore displays current tau PET ligand uptake patterns in
diﬀerent representative cases of cognitively healthy elderly individuals
and patients with early-onset and late-onset AD, respectively. The
ﬁgure is intended to provide an impression of dynamic range and po-
tential oﬀ-target binding patterns without claiming completeness.
After screening three ﬁnal candidates (RO6958948, RO6931643,
and RO6924963) (Gobbi et al., 2017), Roche decided on [18F]
RO6958948 as their lead compound (Wong et al., 2018). Chemically
similar to [18F]FTP (Fig. 1) and presumably binding to the T808
binding site, it is anticipated to exhibit higher aﬃnity to mixed 3R/4R
over isolated 3R or 4R tau pathology. [18F]RO6958948 was reported to
have a lipophilicity of log D=3.22 and rather low plasma free fraction
of 7%. Low non-speciﬁc binding was shown using autoradiography in
tissue from healthy controls, and high grey/white matter ratio in tissue
samples from AD subjects with tau pathology corresponding to Braak
Stage V. No signiﬁcant binding was observed in vitro in PSP, CBD or PiD
tissue samples (Honer et al., 2018). In a ﬁrst-in-man study, 90min
dynamic scans were performed with arterial blood sampling, demon-
strating clear discrimination between healthy controls and AD patients
both using SUVR and volume of distribution estimates (Wong et al.,
2018). For SUVR creation, a 60–90min frame was proposed, corre-
lating well with arterial input-based quantiﬁcation. After 15min, 30%
remained as parent fraction, and the uptake could be described by a
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two-tissue compartment model. No radiolabeled metabolites suspected
to cross the blood-brain barrier were detected. Test-retest variability
was 6–10% depending on brain region and quantiﬁcation method
(SUVR or DVR). [18F]RO6958948 is currently employed in a long-
itudinal study, preliminary results showed increased ligand uptake over
a<1 year follow-up period (Wong et al., 2017).
Following extensive preclinical validation (Walji et al., 2016),
Merck put forward [18F]MK-6240 as lead compound (Hostetler et al.,
2016), demonstrating a Ki = 0.36 nM in NFT-rich AD brain homogenate
versus the high-aﬃnity NFT ligand [3H]-NFT-355, to be compared with
a Ki = 10 μM in amyloid plaque rich AD homogenate versus the amyloid
plaque ligand [3H]-MK-3328 (Hostetler et al., 2016). Compared with
[3H]FTP, [3H]-MK-6240 was found to have a two- to ﬁve-fold higher
binding potential. Non-human primate blocking studies showed no
apparent oﬀ-target binding. Three recently published studies have
evaluated [18F]MK-6240 in vivo (Betthauser et al., 2018; Lohith et al.,
2018; Pascoal et al., 2018). Ligand binding patterns were described in
regions associated with NFT deposition. All studies included dynamic
scanning for between 90 and 180min, demonstrating rapid brain de-
livery and washout, and tracer kinetics were investigated in healthy
controls and AD patients using reference- or blood-input based mod-
elling approaches. Distribution volumes correlated well with SUVR over
either 70–90 (Betthauser et al., 2018; Lohith et al., 2018) or
90–110min (Pascoal et al., 2018). Whereas non-AD tauopathies have
not yet been investigated with [18F]MK-6240, it presumably shares the
same binding site as [18F]FTP and is thus unlikely to exhibit high
Fig. 2. Representative PET scans using diﬀerent current ligands presumably speciﬁc for tau in cognitively healthy elderly individuals (upper rows), patients with
early-onset (EOAD, middle rows) and late-onset Alzheimer's disease (LOAD, lower rows). All images were processed in a uniﬁed manner including co-registration of
PET to its corresponding T1-weighted magnetic resonance imaging (MRI) scan, spatial normalization to Montreal Neurological Institute (MNI) template space and
creation of standardized uptake value ratios (SUVR) using an inferior cerebellum reference region (see (Baker et al., 2017b) for methods). Note that this is not a head-
to-head comparison but merely a display of sample scans from diﬀerent representative cases, obtained at various sites using scanners with diﬀerent spatial resolution,
and non-harmonized image reconstruction. FTP images (80–100min SUVR) were derived from the Berkeley Aging Cohort Study (BACS; University of California,
Berkeley/San Francisco, Drs. William Jagust and Gil Rabinovici), [18F]GTP1 (60–90min SUVR) images were kindly provided by Genentech (Drs. Robby Weimer and
Sandra Sanabria Bohorquez), RO6958948 images (60–90min SUVR) by Roche (Drs. Gregory Klein and Edilio Borroni) and Drs. Dean Wong and Hiroto Kuwabara
from Johns Hopkins University, Baltimore, Maryland, MK6240 images (90–110min SUVR) by Drs. Pedro Rosa-Neto and Tharick Ali Pascoal at McGill University,
Montreal, Canada, and PI2620 scans (60–90min SUVR) by Drs. André Müller and Santaigo Bullich at Life Molecular Imaging GmbH (former Piramal Imaging). Aβ
pos/neg: Amyloid status positive/negative based on Aβ PET scans; MMSE=Mini Mental State Examination.
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aﬃnity to isolated 3R or 4R tau pathology.
Data for the novel [18F]GTP-1 (Genentech Tau Prope-1) and [18F]
PI2620 (Life Molecular Imaging, formerly Piramal Imaging) compounds
have thus far only been presented at conferences. [18F]GTP1 is cur-
rently evaluated in a longitudinal study, preliminary cross-sectional
results demonstrated clearly increased uptake in expected regions in AD
patients as well as an association between ligand uptake and cognitive
impairment. Images showed increased retention in the basal ganglia
relative to background in some subjects but kinetic analysis suggest the
measured SUVR may not necessarily reﬂect speciﬁc tracer binding
(Sanabria Bohorquez et al., 2016; Sanabria Bohorquez et al., 2017;
Weimer et al., 2017).
[18F]PI2620 is structurally similar to FTP (Fig. 1), again suggesting
similar binding preferences to 3R/4R tau. In vitro binding character-
istics were reported for PHF tau deposits (IC50= 3.9 nM), K18 ﬁbrils
(4R, IC50= 8.4 nM), homogenates of AD brain (IC50= 1.9 nM), Pick's
Disease (3R, IC50= 2.6 nM), and PSP (4R, IC50= 10.7 nM), indicating
high aﬃnity to 3R/4R tau deposits but potentially also 3R inclusions
(Stephens et al., 2018). No binding to β-amyloid or MAO-A/B was re-
ported. [18F]PI2620 is currently evaluated in several clinical trials, in-
cluding a test/retest study with arterial sampling. Initial in vivo data
showed robust brain uptake and fast wash-out in non-target regions, no
lipophilic metabolites, and 20% of the intact tracer in blood at 60min
p.i. (Seibyl et al., 2017). SUVR over a 60–90min p.i. time frame were
highly correlated with DVR and showed clear discrimination between
AD patients and control individuals, as well as high correlation between
test-retest results (Stephens et al., 2018).
4. Tau PET imaging in aging and Alzheimer's disease
4.1. Topography of tau ligand retention
Based on years of neuropathological evidence from autopsies, the
presence and location of pathological tau accumulations in the human
brain are well established (Braak and Braak, 1991). These studies have
proposed a progression of stages of tau deposition based on cross sec-
tional autopsy data (see Fig. 3A). These stages begin with tau deposits
in the entorhinal cortex (Braak stages I/II), moving to inferolateral
temporal cortex and parts of the medial parietal lobe (stages III/IV),
and eventually throughout association cortex (V/VI). Interestingly,
stages III/IV can be seen in both CU older people and those with AD
while stages I/II are common in those who are cognitively normal and
stages V/VI are almost universally associated with dementia (Bennett
et al., 2006; Hyman et al., 2012).
The relatively recent advent of relevant PET radioligands has per-
mitted the in vivo detection of tau which largely parallels these autopsy
ﬁndings (see Fig. 3B). The radioligand [18F]FTP has been most widely
studied so far and binds with high aﬃnity to PHF tau in AD patients
(Chien et al., 2013; Lowe et al., 2016; Marquie et al., 2015). Tau tracer
retention in aging and AD appears to follow a particular topography
(e.g. Cho et al., 2016a) and although longitudinal data are sparse (Jack
Jr. et al., 2018b; Southekal et al., 2018), the distribution can be cap-
tured as a regional pattern that appears to begin in entorhinal cortex,
spreading through inferolateral temporal lobes and medial parietal
lobes and eventually to wide areas of the neocortex. In contrast to Aβ,
which is often found throughout neocortex in a regionally less speciﬁc
manner using PET imaging, the quantitation of tau deposition requires
careful selection of region-speciﬁc measures of tracer retention. A
number of diﬀerent approaches have been suggested included regional
and global measures for binary categorization (Jack Jr. et al., 2017;
Maass et al., 2017; Mishra et al., 2017; Wang et al., 2016) as well as
topographical staging approaches that recapitulate ex vivo pattern of
hierarchical tau spread (Maass et al., 2017; Schöll et al., 2016; Schwarz
et al., 2016). Quantiﬁcation from large regions may be suﬃcient to
capture AD-related tau PET signal and progressive within-person ac-
cumulation of pathologic tau (Jack Jr. et al., 2018b; Maass et al., 2017).
The high regionality of brain tau load as visualized with PET is further
emphasized by studies employing data-driven approaches without prior
deﬁnition of anatomical regions (Sepulcre et al., 2017a; Whitwell et al.,
2018b).
4.2. Eﬀects of Aβ and age on patterns of tau PET ligand uptake
Elevated tau tracer binding in the medial temporal lobe (MTL) is
commonly seen in CU elderly, whereas widespread binding in neocor-
tical regions usually requires the presence of aggregated Aβ (Cho et al.,
2016a; Gordon et al., 2016; Johnson et al., 2016; Lockhart et al., 2017b;
Maass et al., 2017; Pontecorvo et al., 2017; Schöll et al., 2016; Schwarz
et al., 2016; Sepulcre et al., 2016).
Interestingly, although there is an overall correlation between the
amount of Aβ in the brain and the amount of tau (Johnson et al., 2016),
the spatial locations of these two aggregated proteins are discordant.
Speciﬁcally, Sepulcre and colleagues (Sepulcre et al., 2016) demon-
strated strong positive local-to-local tau versus Aβ PET correlations in
lateral temporal, frontal and parietal lobes across 88 CU elderly, but tau
in these regions further correlated with Aβ throughout the brain. Data
Fig. 3. Tau tracer uptake patterns re-
semble ex vivo Braak stages.
A. Schematic display of Braak stages in
the development of Alzheimer's dis-
ease-associated tau pathology based on
post mortem data. Reprinted from
“Stages of the Pathologic Process in
Alzheimer Disease: Age Categories
From 1 to 100 Years,” (Braak et al.,
2011). Copyright 2011 by Oxford Uni-
versity Press B. Voxel-wise two-sample
t-tests on Flortaucipir SUVR images
between subjects assigned to con-
tiguous tau-PET based Braak stages.
Results are Family-Wise Error (FWE)
corrected at voxel level (pvoxel < 0.05,
k > 100). Individuals included cogni-
tively normal adults and AD patients.
See (Maass et al., 2017) for more in-
formation.
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from Lockhart and colleagues (Lockhart et al., 2017b) conﬁrmed these
ﬁndings in 46 CU showing that tau PET signal in the temporal lobe and
some frontal areas correlated with Aβ measures among widespread
neocortical regions (see Fig. 4). Together these data indicate a regional
vulnerability of temporal brain regions to tau regardless of where Aβ is
deposited. Notably, associations between global Aβ and regional tau
PET signal seems to be strongest in the entorhinal cortex (Vemuri et al.,
2017) as demonstrated in in large sample of 420 CU elderly, suggesting
that this “early tau region” should be included in meta regions for de-
tection of AD-related tau PET signal.
Extra-MTL tau deposition is more common in those with AD, al-
though elevated tau tracer signal in neocortical areas such as inferior
temporal or occipital cortex has been reported in those who are cog-
nitively normal and even Aβ-negative (Lowe et al., 2018a; Lowe et al.,
2018b). While on average AD patients have more widespread and se-
vere tau deposition than controls, some AD patients who are Aβ-posi-
tive may in fact show relatively low levels of tau deposition (one pos-
sibility is that such patients are clinically misdiagnosed and have
incidental Aβ-co-pathology) (Pontecorvo et al., 2017; Wang et al.,
2016).
More Aβ deposition is not only associated with more tau deposition
in cross sectional studies, but longitudinal studies have also shown that
increasing levels of brain Aβ predict more tau deposition after several
years in limbic and neocortical Braak regions even in those who are
nominally Aβ-negative (Leal et al., 2018; Tosun et al., 2017). Long-
itudinal data also suggest that Aβ facilitates the spread of tau from the
MTL to the medial parietal cortex through the cingulum bundle in the
normal older brain (Jacobs et al., 2018). Although there are still rela-
tively limited longitudinal data, it appears that longitudinal tau
accumulation is measurable in the temporal lobes in cognitively normal
individuals and those with AD, although changes have not been de-
tected in those who are Aβ-negative (Jack Jr. et al., 2018b; Southekal
et al., 2018).
Compared to associations with Aβ, correlations between tau PET
measures and age across CU elderly seem to be weaker and be conﬁned
to MTL regions (Maass et al., 2018; Schöll et al., 2017b). Among 83 CU
(Maass et al., 2018), both Aβ and age independently predicted MTL FTP
uptake, with age only accounting for 8% of the variance compared to
25% variance explained by global Aβ. When age eﬀects in CU adults
with normal levels of Aβ were studied across the life span (Lowe et al.,
2018b), modest age-related increases in tau PET signal were found in
most regions of the brain. Strongest diﬀerences in tau tracer binding
between young and elderly subjects are usually seen in choroid plexus
and basal ganglia, but these are thought to reﬂect oﬀ-target binding
(Lowe et al., 2016; Lowe et al., 2018b).
Age of symptom onset among AD patients clearly aﬀects tau PET
uptake patterns. Sporadic early-onset AD patients (EOAD) exhibit dis-
tinctly greater parietotemporal and frontal ligand uptake when com-
pared with LOAD which exhibits rather conﬁned temporal lobe uptake
(Schöll et al., 2017a) (see also Fig. 2). Data from studies in early-onset
familial/autosomal-dominant AD are limited, suggesting earliest FTP
uptake in the MTL of Aβ-positive presymptomatic mutation carriers but
high cortical uptake, spatially comparable to sporadic EOAD cases in
later symptomatic stages (Quiroz et al., 2018; Schöll et al., 2017a).
In summary, tau PET imaging data indicate that tau deposition
occurs on a continuum from normal aging through AD, likely beginning
in the entorhinal cortex within the MTL in normal aging and increasing
in both quantity and distribution with the deposition of Aβ and the
Fig. 4. Association between global Aβ and regional tau PET measures in cognitively normal elderly.
A. Partial correlation (r-values) of global PiB with regional FTP PET measures in 420 cognitively normal individuals (age 50+) after adjusting for age. Highest
correlations were in medial temporal regions, speciﬁcally entorhinal cortex (ERC). Reprinted from “Tau-PET uptake: Regional variation in average SUVR and impact
of amyloid deposition,” (Vemuri et al., 2017). Copyright 2017 by Elsevier Inc. (on behalf of the Alzheimer's Assocation) B. Mean partial correlation r values for
associations between global PiB DVR and FTP SUVR in diﬀerent ROIs in 46 normal elderly from BACS, demonstrating strongest correlation in temporal lobe. Adapted
from “Amyloid and tau PET demonstrate region-speciﬁc associations in normal older people,” (Lockhart et al., 2017b). Copyright 2017 by Elsevier.
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progression towards AD with clearly diﬀerent patterns in EOAD and
LOAD.
4.3. Relationships between tau PET, cognition, and measures of
neurodegeneration
For years, the role of Aβ in the development of AD has been per-
plexing because of the relatively weak association between measure-
ments of this protein in the brain and concomitant measures of cogni-
tive decline, whether in autopsy studies (Nelson et al., 2012), cross
sectional imaging-cognition studies (Hedden et al., 2013; Jansen et al.,
2018), or longitudinal imaging studies (Donohue et al., 2017; Dubois
et al., 2018). It now seems likely that this weak relationship may be
explained by the intermediary factor of tau, which is correlated with
both Aβ and cognition. Greater tau tracer retention is related to both
poorer cognitive function cross-sectionally, and decline in cognition
longitudinally although this decline has generally been measured ret-
rospectively because of the relative novelty of tau imaging
(Aschenbrenner et al., 2018; Maass et al., 2018; Schöll et al., 2016).
4.4. Findings in cognitively normal elderly
While most tau PET studies examined tau–cognition relationships in
samples that included symptomatic patients with MCI or AD dementia
(Aschenbrenner et al., 2018; Brier et al., 2016; Cho et al., 2016b;
Johnson et al., 2016; Maass et al., 2017; Ossenkoppele et al., 2016;
Schwarz et al., 2016), a few studies focused on CU elderly (Buckley
et al., 2017; Maass et al., 2018; Mishra et al., 2017; Schöll et al., 2016;
Shimada et al., 2017b). Within CU elderly, associations are most
strongly seen between episodic memory measures and tau tracer uptake
in the temporal lobe (particularly entorhinal cortex, see Fig. 5), whereas
associations with global cognition are either absent or found with tau
PET signal in wider neocortical regions. Global Aβ does not seem to
alter or account for the eﬀect of MTL tau on episodic memory in these
CU individuals (Schöll et al., 2016, Maass et al., 2018; Fig. 5A). Inter-
estingly, similar associations have been seen between entorhinal tau
load and subjective cognitive decline (Buckley et al., 2017), and these
were also not altered by Aβ status. The likelihood that MTL tau accu-
mulation is not a benign event in early stages is supported by associa-
tions between tau deposition and both brain atrophy and glucose hy-
pometabolism in CU older people that are topographically similar to the
patterns seen in patients with AD (Adams et al., 2018; Das et al., 2018;
Gordon et al., 2018; Hanseeuw et al., 2017; LaPoint et al., 2017).
4.5. Findings in patients
Relationships between tau deposition, cognition, and measures of
neurodegeneration are stronger yet in patients with AD. Initial studies
conﬁrmed an association between tau deposition and cognition that is
stronger than the association between Aβ and cognition (Brier et al.,
2016; Johnson et al., 2016). Associations with cognition are particu-
larly striking in cases of EOAD that frequently present with dysfunction
in language, visuospatial, or executive systems. In these syndromes, tau
deposition bears a strong relationship to clinical phenotype, a re-
lationship that is not seen between Aβ and clinical ﬁndings
(Ossenkoppele et al., 2016; Xia et al., 2017). In AD patients, tau de-
position is also associated with the neurodegenerative biomarkers of
atrophy and glucose hypometabolism (Bischof et al., 2016; Iaccarino
et al., 2018; Wang et al., 2016). This is also particularly marked in the
syndromic variants of EOAD wherein patterns of atrophy and hypo-
metabolism correlate better with tau than with Aβ (Ossenkoppele et al.,
2016). In fact, while cognition is explained by both atrophy and tau,
after accounting for atrophy tau remains correlated with cognitive
function in multivariate models (Bejanin et al., 2017). EOAD has also
been associated with more severe glucose hypometabolism that has not
been explained by the amount or distribution of Aβ (Rabinovici et al.,
Fig. 5. Tau PET signal relates to episodic
memory performance in cognitively normal
elderly.
A. Higher Braak I/II FTP SUVR (mean
across entorhinal cortex and hippocampus
after partial volume correction) relates to
worse episodic memory (Z-score of verbal
and visual recall) in 83 older adults from
BACS. R denotes skipped Pearson correla-
tion coeﬃcient with bootstrapped 95% CI
from robust correlations; outliers colored in
black. See Maass et al., 2018 for details. B.
Higher mean FTP SUVR across amygdala,
entorhinal, lateral occipital and inferior
temporal cortex relates to worse episodic
memory in elderly sample from WashU.
Adapted from “AV-1451 PET imaging of tau
pathology in preclinical Alzheimer disease:
Deﬁning a summary measure,” by Mishra
et al., 2017, Neuroimage, 161:171–178.
Copyright 2017 by Elsevier C. Voxel-wise
regressions of episodic memory on FTP
SUVR in subjects from A. (whole brain,
pcluster < 0.05, pvoxel < 0.001, no explicit
mask). Signiﬁcant regions include bilateral
entorhinal/parahippocampal cortex, left
inferior temporal gyrus and middle tem-
poral gyrus.
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2010). The interplay between tau patterns and variants of AD is also
seen in studies that include both EOAD and LOAD patients. For ex-
ample, most patients with relatively low FTP binding in the entorhinal
cortex, compared to overall cortical binding, have EOAD with atypical
clinical presentations, while most patients with high FTP binding in
both entorhinal and neocortex have EOAD with typical amnestic pre-
sentation, and most with low FTP binding in both entorhinal and
neocortex have late onset typical AD (Whitwell et al., 2018b). Diﬀer-
ences in tau patterns have also been detected when stratifying by APOE
ε4-status. AD patients that carry the APOE ε4 risk allele have lower
overall cortical FTP binding (especially in the parietal and occipital
cortex) but relatively higher binding in the entorhinal cortex compared
to APOE ε4-negative AD patients, with corresponding diﬀerences in
atrophy patterns (in a mix of EOAD and LOAD patients, without age
diﬀerences between the APOE-groups) (Mattsson et al., 2018a).
Thus, the measurement of tau accumulation in aging and AD has
revealed a pattern of deposition that parallels neuropathological data
but oﬀers the possibility of prospective longitudinal studies. The strong
relationship between tau and both neurodegeneration and cognition,
along with its relationship with Aβ suggest that it may well be the
“missing link” in establishing a relationship between amyloid-β and the
downstream structural, functional, and molecular events that are linked
to cognitive decline and dementia. This emphasizes the need to un-
derstand how Aβ relates to the development of tau pathology in AD, a
question that remains largely unanswered.
4.6. Tau PET and brain connectivity
Over the last decade, the spatial correspondence between Aβ PET
burden and intrinsic connectivity networks has been extensively stu-
died, and prominent overlap with the default mode network (DMN) has
been observed (Buckner et al., 2005; Grothe et al., 2016; Sperling et al.,
2009). With the availability of tau PET imaging, topographical simila-
rities between tau pathology and functional brain networks have been
recently explored (Hansson, Grothe et al., 2017; Hoenig et al., 2018). In
the study by Hansson and colleagues, AD-related tau PET signal pri-
marily overlapped with the dorsal attention network and to a lower
extent with higher visual, limbic and DMN network components.
Hoenig et al., 2018, who identiﬁed independent coherent networks of
AD-related tau PET signal, also observed a spatial correspondence of
tau seed-based functional networks with multiple resting-state net-
works. In their data, spatial similarities were highest with ventral and
dorsal DMN but also evident with salience, language, primary and
higher visual, as well as hippocampal networks. Together these ﬁndings
indicate that tau pathology does not exclusively distribute along one
particular network.
Other studies characterized the spatial associations of tau and Aβ
PET load with functional connectivity changes in the brains of CU el-
derly (Schultz et al., 2017; Sepulcre et al., 2017b) and AD dementia
patients (Cope et al., 2018; Jones et al., 2017; Wiepert et al., 2017).
Among older adults, an inverse relationship of tau versus Aβ PET
measures with functional connectivity hubs was observed such that tau
tended to be located in areas of hypoconnectivity (e.g. temporal lobe)
but Aβ in areas of hyperconnectivity (e.g. occipital and parietal lobe)
(Sepulcre et al., 2017b). Schultz and colleagues (Schultz et al., 2017)
furthermore showed an interactive eﬀect of global Aβ and neocortical
tau PET measures on functional connectivity. While hyperconnectivity
in DMN and salience networks was seen in OA with high Aβ but low
levels of inferior temporal tau, hypoconnectivity was present when both
global Aβ and neocortical tau were high. These cross-sectional ﬁndings
could be interpreted as support for a phase of hyperconnectivity in Aβ-
positive aging, followed by a loss of connectivity with spread of tau to
neocortical regions in the progression of AD.
The cascading network failure model proposed by Jones and col-
leagues (Jones et al., 2016) incorporated ﬁndings about the relationship
between tau, Aβ and functional network changes (Jones et al., 2017;
Wiepert et al., 2017). The model suggests that local tau-associated
network disruptions (e.g. in temporal lobe) lead to compensatory load
shift to the posterior DMN and subsequently other connectivity hubs
(evident as increased connectivity) that are associated with amyloidosis
and network failure. Longitudinal data across the AD spectrum will be
necessary to elucidate the sequential order of tau and Aβ accumulation
and associated functional network changes.
5. Oﬀ-target binding of tau PET ligands
Oﬀ-target binding of tau PET ligands is one of the current major
limitations and challenges to be addressed in novel tracer development
(see also (Bischof et al., 2017, Lemoine et al., 2018, Lois et al., 2018) for
recent reviews).
5.1. Flortaucipir (FTP)
Among tracers, FTP oﬀ-target binding has been characterized best
and has been most frequently reported in the basal ganglia, substantia
nigra, choroid plexus, meninges and vessels (see also Fig. 2).
5.1.1. Basal ganglia and substantia nigra
The strong FTP uptake in caudate, putamen, and pallidum seen in
elderly individuals regardless of their clinical diagnosis (e.g. (Baker
et al., 2017b, Brier et al., 2016, Lowe et al., 2016, Vemuri et al., 2017,
Winer et al., 2018)) has been attributed to iron binding. In groups of
patients and controls, basal ganglia FTP signal correlated with age-re-
lated increases in iron accumulation measured by iron-sensitive R2*
MRI (Choi et al., 2018).
Similarly, FTP binds strongly to substantia nigra, also in cases with
no tau pathology, which has been related to neuromelanin (Marquie
et al., 2015; Marquie et al., 2017b; Marquie et al., 2017c). This is in
accordance with reduced substantia nigra FTP signal seen in PD pa-
tients without (Hansen et al., 2016) or with (Smith et al., 2018) de-
mentia compared to age-matched controls, that might reﬂect decreases
in neuromelanin containing dopaminergic neurons (but see Winer et al.,
2018 for diﬀerent ﬁndings). Other neuromelanin and melanin con-
taining structures that show elevated FTP binding include pituitary,
retinal pigment epithelial cells, leptomeninges, and malignant mela-
nocytes in metastatic melanoma (Lowe et al., 2016; Marquie et al.,
2015; Marquie et al., 2017b).
5.1.2. Choroid plexus
High FTP signal in choroid plexus is commonly seen in older in-
dividuals and interferes with quantiﬁcation of hippocampal uptake due
to the close proximity of both structures. In choroid plexus, FTP signal
has been shown to co-localize with calciﬁcation/mineralization (Lowe
et al., 2016). Histology data has further suggested that there might be
“on-target” binding in the choroid plexus to tangle-like structures cor-
responding to Biondi “ring” tangles (Ikonomovic et al., 2004). More-
over, melanocyte FTP binding might partially account for high choroid
plexus signal (Marquie et al., 2015; Marquie et al., 2017c) as proposed
by race diﬀerences seen between Black/African American and white
participants from the Harvard Aging Brain Study (HABS) (Lee et al.,
2018).
PVC approaches that include choroid plexus (Baker et al., 2017b;
Wolters et al., 2018) as region of interest can help to reduce spill-in
eﬀects of choroid plexus signal to hippocampal signal (Lee et al., 2018;
Maass et al., 2017; Maass et al., 2018; Schöll et al., 2016).
5.1.3. MAO
In vitro data (Vermeiren et al., 2018) showed that FTP binds to
MAO-A and B at a similarly high aﬃnity as it binds to tau ﬁbrils in brain
homogenates. MAO-B is a protein highly expressed in all brain regions
and increases with age (e.g. Fowler et al., 1997). Hansen and colleagues
(Hansen et al., 2018), however, did not observe signiﬁcant diﬀerences
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in vivo between FTP scans of non-demented PD patients with and
without MAO-B inhibitors, suggesting that FTP does not bind sig-
niﬁcantly to MAO-B in vivo.
Increased FTP signal is further seen in blood vessels, hemorrhages
and infarcts, and suggests binding to blood components (Lockhart et al.,
2017a; Lowe et al., 2016; Marquie et al., 2015).
5.2. Other tau PET ligands
Similar oﬀ-target binding proﬁles as seen for FTP have been de-
scribed for [11C]PBB3 and [18F]THK compounds with oﬀ-target
binding in choroid plexus, basal ganglia, substantia nigra and meninges
(Betthauser et al., 2017b; Chiotis et al., 2018; Lemoine et al., 2017).
For [18F]THK5351, strong binding to MAO-B has been demon-
strated in vivo and ex vivo (Harada et al., 2018; Ng et al., 2017b). In
particular, application of the MAO-B inhibitor selegiline in eight pa-
tients reduced regional SUVRs by>50% in the thalamus and basal
ganglia, and> 40% in cerebellar cortex, preventing accurate quantiﬁ-
cation of tau levels by means of this tracer (Ng et al., 2017b).
Second-generation tau tracers (see above) seem to be hampered less
by oﬀ-target binding (see also Fig. 2), however, most of these results
have to be replicated in larger samples in vivo. For instance, preclinical
evaluation of three novel Roche compounds ([18F]RO6958948, [11C]
RO6931643 and [11C]RO6924963) suggests lack of any signiﬁcant oﬀ-
target binding in vitro demonstrated by autoradiography and displace-
ment studies (Honer et al., 2018). In vivo imaging with [18F]MK6240 in
a sample of patients and OA revealed oﬀ-target binding to ethmoid
sinus, clivus, meninges, substantia nigra, but not the basal ganglia or
choroid plexus (Betthauser et al., 2018; Pascoal et al., 2018). Although
the lack of oﬀ-target binding to choroid plexus is a major advance al-
lowing quantiﬁcation of hippocampal signal, ethmoid sinus uptake that
spills into the orbitofrontal cortex and meningeal uptake aﬀecting
various cortical regions does still limit quantiﬁcation in these areas (see
Fig. 2). Deﬂuorination of MK-6240 yields a low bone signal (Lohith
et al., 2018) at late scanning time points that does likely not aﬀect the
quantiﬁcation of cortical signal. It has been speculated that tracer ac-
cumulation around the skull might derive from a non-brain penetrant
circulating metabolite. Considering extracortical hotspots in PVC ap-
proaches might thus be useful for all current tau PET tracers (Baker
et al., 2017b).
6. Tau PET ﬁndings in other tauopathies
Autoradiography studies in post mortem tissue have so far found only
weak to moderate binding of existing tau PET ligands to pure 3R- or 4R
tau pathology, suggesting limited usefulness in tauopathies such as PSP,
CBD, PiD, diseases within the tau-associated fronto-temporal dementia
spectrum (FTDP-17), or neurodegenerative disorders associated pre-
dominantly with alpha-synuclein or TDP-43 pathology (Josephs et al.,
2016; Lowe et al., 2016; Marquie et al., 2017a; Marquie et al., 2015;
Sander et al., 2016). One study reported that post mortem tau neuro-
pathology correlated with regional hypometabolism but not ante
mortem FTP uptake in a case of PSP (Smith et al., 2017b). Nevertheless,
several studies have investigated in vivo tau PET ligand uptake in non-
AD tauopathies, albeit generally in small samples.
Increased subcortical [18F]FTP and [18F]THK5351 uptake was
found in PSP patients, mainly in midbrain structures and the basal
ganglia (Cho et al., 2017; Ishiki et al., 2017; Smith et al., 2017a;
Whitwell et al., 2018a). Clinical relevance and interpretation of these
ﬁndings might be compromised by age-related and oﬀ-target ligand
binding in these areas. Interestingly, one study reported an association
between higher FTP uptake impairment of functional connectivity in
PSP (Cope et al., 2018).
In vivo data from CBS (corticobasal syndrome) patients proposed
that FTP PET might be useful for distinguishing e.g. CBD pathology from
AD or PSP (Josephs et al., 2016; Smith et al., 2017c). Weakly increased
uptake was demonstrated in subcortical structures, the motor cortex in
the hemisphere contralateral brain to the most aﬀected body side, and
white matter tracts corresponding to the cortoco-spinal tract (Smith
et al., 2017c). However, grey matter atrophy was more pronounced and
not associated with FTP uptake in these patients.
Finally, slightly elevated cortical tau PET uptake has been observed
in Dementia with Lewy bodies (DLB) and Parkinson's disease dementia
(PDD) (Smith et al., 2018) while substantia nigra signal was decreased
in Parkinson's disease (PD) (Cho et al., 2017; Coakeley et al., 2018;
Smith et al., 2018). In PDD patients, cognitive impairment was corre-
lated with increased tau burden. Another study reported no diﬀerence
in cortical FTP uptake between CU elderly, patients with PD-MCI and
PD without cognitive impairment (Winer et al., 2018).
Further in vitro and in vivo studies are needed, especially for second-
generation tau ligands, to inform the use of tau PET in non-AD neuro-
degenerative disorders.
7. Concordance between imaging and ﬂuid biomarkers for tau
To our knowledge, only six studies have simultaneously tested CSF
tau biomarkers and tau PET imaging (using data from four diﬀerent
cohorts). Some studies have largely focused on CU individuals (Brier
et al., 2016; Chhatwal et al., 2016; Gordon et al., 2016), while others
have focused more on symptomatic stages of AD (La Joie et al., 2018;
Mattsson et al., 2017b; Mattsson et al., 2018b), or other neurodegen-
erative diseases (La Joie et al., 2018). All these studies used FTP PET.
Chhatwal et al. (Chhatwal et al., 2016) tested 31 CU persons from
HABS, with CSF biomarkers analyzed by the AlzBio3 assays, and FTP
quantiﬁed in predeﬁned ROIs. Correlations between CSF biomarkers
and FTP were strongest for CSF P-tau, and were signiﬁcant in total
cortex, several temporal ROIs and a parietal ROI (the strongest corre-
lation was seen in inferior temporal cortex). Both CSF T-tau and P-tau
were signiﬁcantly correlated with FTP in entorhinal, parahippocampal,
middle temporal, and inferior temporal cortex.
Brier et al. (Brier et al., 2016) tested 31 CU and 5 impaired persons
(two CDR 0.5 and three CDR > 0.5) from a St Louis cohort, with CSF
biomarkers analyzed by INNOTEST assays. The mean grey matter FTP
correlated with greater CSF T-tau (but not signiﬁcantly with P-tau).
Brier et al. used an elastic net procedure to deﬁne regional PET “to-
pographies”. The strongest contributions to prediction of CSF T-tau
came from cuneus, entorhinal cortex, transverse temporal sulcus, and
(with a negative coeﬃcient) hippocampus. The authors found similar
topographies for P-tau. In another study from the St Louis cohort,
Gordon et al. (Gordon et al., 2016), studied 41 CU (15 of these were
Aβ+deﬁned by [11C]PiB or [18F]FTP PET imaging) and 11 impaired
persons (seven CDR 0.5, four CDR > 0.5; 10 of these were Aβ+). In
the entire cohort, there were signiﬁcant relationships for all CSF bio-
markers and FTP, but when the correlations were restricted to CU, CSF
T-tau and P-tau were no longer associated with FTP (but reduced CSF
Aβ42 was associated with greater FTP in both the whole cohort and in
CU).
In the Swedish BioFINDER cohort, Mattsson et al. tested 30 CU (15
of these were Aβ+deﬁned by CSF Aβ42), 14 prodromal AD
(Aβ+MCI) and 39 AD dementia (all Aβ+) patients, with CSF bio-
markers analyzed by INNOTEST assays. CSF T-tau and P-tau were
moderately associated with retention of FTP, and associations were
mainly seen in the dementia group (Mattsson et al., 2017b). Voxelwise
analyses (adjusted for diagnostic group) showed widespread associa-
tions in frontal, temporal and parietal regions between the CSF bio-
markers and FTP, with more prominent associations for T-tau than P-
tau. CSF tau biomarkers were increased in preclinical AD, while FTP
was more strongly increased in symptomatic stages of the disease. In
line with this, FTP but not CSF T-tau or P-tau, was strongly associated
with atrophy and results on cognitive tests, (even when adjusting for
diagnostic group). When using dichotomous classiﬁcations, regional
FTP and CSF tau measures were most often concordant, especially in
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dementia patients. Another paper on the same cohort presented diag-
nostic accuracies for the diﬀerent biomarkers (Mattsson et al., 2018b).
The diagnostic accuracies for prodromal AD versus CU were similar for
CSF tau biomarkers (both T-tau, AUC 0.86; and P-tau, AUC 0.94) and
FTP (using a temporal lobe composite, AUC 0.92), while FTP had su-
perior accuracy for AD dementia versus CU (AUC 1.00; T-tau, AUC 0.88;
P-tau, AUC 0.89).
In a study on a UCSF cohort, La Joie et al. (La Joie et al., 2018)
tested 28 AD patients (3 with prodromal AD and 25 with AD dementia)
and 25 non-AD neurodegenerative patients. CSF biomarkers were
analyzed by AlzBio3. Cortical FTP and P-tau both had excellent dis-
crimination for Aβ-positive AD versus non-AD conditions (AUC
0.92–0.94), with high classiﬁcation agreement (83%). When restricted
to Aβ-positive patients with AD, FTP correlated modestly with both P-
tau and T-tau. Regionally, FTP correlated with CSF P-tau in tempor-
oparietal cortices and with T-tau in medial prefrontal regions. Within
AD, MMSE scores were associated with FTP, but not CSF biomarkers.
In summary, these six studies found that CSF tau measures were
moderately correlated with FTP, with strongest correlations in symp-
tomatic stages of AD, and weaker or non-signiﬁcant correlations in CU.
CSF T-tau and P-tau were similarly correlated to FTP in CU and AD
(Brier et al., 2016; Chhatwal et al., 2016; Gordon et al., 2016; Mattsson
et al., 2017b; Mattsson et al., 2018b), but when non-AD neurodegen-
erative patients were included, P-tau rather than T-tau provided more
FTP-like information (La Joie et al., 2018). This suggests that in non-AD
conditions, these CSF biomarkers may be diﬀerentially regulated, per-
haps because T-tau (but not P-tau) secretion is increased in a non-dis-
ease speciﬁc fashion due to neuronal injury. Another common ﬁnding
was that cognitive measures (La Joie et al., 2018; Mattsson et al.,
2017b) and atrophy (Mattsson et al., 2017b) were related to FTP but
not to CSF tau measures (when adjusting for clinical diagnosis of AD,
otherwise CSF tau measures are strongly correlated to both atrophy and
cognition, as shown many times before). One possible interpretation is
that CSF tau biomarkers reach a plateau during the prodromal stage of
the disease, when the FTP uptake still continues to increase. One study
(Mattsson et al., 2017b) suggested that changes in CSF tau measures
may be detectable before changes in the FTP signal. Notably, the overall
results were quite similar between the diﬀerent studies, despite the use
of diﬀerent methods for FTP quantiﬁcation, diﬀerent CSF assays and
diﬀerent statistical procedures.
The diﬀerent dynamics of imaging and ﬂuid markers of tau pa-
thology at diﬀerent stages of AD may have implications for their use in
clinical trials and practice. Taken together, the results suggest that CSF
tau biomarkers have properties that make them suitable for the iden-
tiﬁcation of “disease state”, i.e. the presence of a pathological process
associated with AD. Their relative lack of dynamic changes later during
the disease and their poor correlation with measures of cognition and
atrophy at the symptomatic stages of AD make them less suitable as
markers of “disease stage”. In contrast, tau PET imaging may lack
sensitivity very early in the disease, but the continuous accumulation of
signal, and the strong correlations with cognition and atrophy make tau
PET imaging a powerful marker of “disease stage” in AD.
8. Conclusions and future perspectives
The availability of techniques to measure and map Aβ transformed
clinical and translational research on aging and dementia many years
ago. Now, within the past several years, methods of measuring tau
pathology in the brain, following the earlier development of tau mea-
sures in CSF, have furthered this transformation. The clearest example
of this is the proposal of a new framework for biomarker applications in
which the conjoint presence of Aβ and tau pathology, regardless of the
presence or nature of symptoms, establishes an individual as having AD
(Jack Jr. et al., 2018a). While this approach is not proposed for clinical
use, the research deﬁnition of AD as a biological entity, as opposed to a
clinical syndrome, will further mechanistic studies and therapeutic
developments. These advances in both methods and concepts have of
course not yet lead to an eﬀective treatment for AD. However, the
availability of both Aβ and tau biomarkers derived from both bodily
ﬂuid analyses and brain imaging is changing the landscape of human
AD research.
Measurement of tau in CSF and brain are relatively recent devel-
opments, and longitudinal data, especially for tau PET, are only just
being acquired. Longitudinal studies of both Aβ and tau biomarkers,
paired with measurements of neurodegeneration and cognition, will be
necessary to establish temporal relationships between molecular events.
These studies will take time to accrue the necessary samples, but should
pay oﬀ in important scientiﬁc knowledge. Some of the most basic
questions in the ﬁeld involve the relationships between Aβ and tau, and
how or whether one protein leads to aggregation of the other. Similarly,
the time course of aggregation, spread, and pathological eﬀects needs to
be elucidated. Large, longitudinal cohort studies using multiple bio-
markers will be crucial in answering these basic questions.
Use of biomarkers in the development of therapeutic trials is also
important and growing. We have already witnessed new approaches
based on measurement of Aβ; clinical trials using Aβ-lowering therapies
now require measurement of Aβ for enrollment and usually measure
treatment eﬀects on biomarkers to track target engagement. Tau mea-
surements are sure to serve similar roles in the development of anti-tau
therapeutics. Furthermore, tau may be useful in providing a measure of
disease progression even for therapeutic approaches that do not target
tau directly. That is, therapies may be targeted to a “sweet spot” such
that symptoms are at a stage where amelioration is possible, but
treatment is not yet futile. Tau measurements may help to identify this
timing.
There are indeed many major technical and methodological chal-
lenges yet to overcome. For PET, while Aβ imaging agents seem to be
largely comparable and methods for their quantitative comparison have
been proposed (i.e., the CENTILOID approach (Klunk et al., 2015)), it is
not clear that this is the case for tau ligands. Some tau ligands have not
yet seen wide application, and methods for quantitation even for a
single tracer are not uniformly established. Comparability across
methods and tracers will require attention, as will the assessment of
comparability between ﬂuid- and imaging-derived biomarkers.
Finally, it is increasingly recognized that Aβ and tau biomarkers,
while the most ubiquitously expressed pathologically aggregated pro-
teins, are not the only ones involved in neurodegenerative diseases.
Methods for measurement of alpha-synuclein and TDP-43 will likely be
important in establishing an even more complete picture of the brain in
aging and dementia.
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